📣 New hope for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy!
At the ASCO 2025 conference, the results of a new Phase 3 study called ASCENT-03 were presented.
The study evaluated the efficacy of the drug Trodelvy in women with metastatic TNBC who are not eligible for immunotherapy.
🔬 Study details in brief:
Approximately 540 women participated.
One group received Trodelvy.
The second group received physician’s choice chemotherapy.
📊 Results:
The Trodelvy group showed a significant improvement in progression-free survival (PFS).
No unusual side effects were reported.
🩺 Dr. Javier Cortes, the lead investigator, stated that this is the most significant advancement in over 20 years for this group of patients.
🔗 For more information:
Click to read
Yours,
Nir Erez | Trial-In Pharma
